Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Mario Ponce; Cesar Ugarte-Gil; Carlos Zamudio; Fiorella Krapp; Eduardo Gotuzzo; Carlos Seas

doi:10.1016/j.trstmh.2012.05.008

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Mario Ponce, Cesar Ugarte-Gil, Carlos Zamudio, Fiorella Krapp, Eduardo Gotuzzo, Carlos Seas

Research output: Contribution to journal › Article › peer-review

Abstract

The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.

Original language	English (US)
Pages (from-to)	508-510
Number of pages	3
Journal	Transactions of the Royal Society of Tropical Medicine and Hygiene
Volume	106
Issue number	8
DOIs	https://doi.org/10.1016/j.trstmh.2012.05.008
State	Published - Aug 2012
Externally published	Yes

Keywords

Drug therapy
Failure
Multi-drug resistance
Streptomycin
Treatment outcome
Tuberculosis

ASJC Scopus subject areas

Parasitology
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.trstmh.2012.05.008

Cite this

@article{c86cc848cb62485fac610d1ea737bb8c,

title = "Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru",

abstract = "The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.",

keywords = "Drug therapy, Failure, Multi-drug resistance, Streptomycin, Treatment outcome, Tuberculosis",

author = "Mario Ponce and Cesar Ugarte-Gil and Carlos Zamudio and Fiorella Krapp and Eduardo Gotuzzo and Carlos Seas",

year = "2012",

month = aug,

doi = "10.1016/j.trstmh.2012.05.008",

language = "English (US)",

volume = "106",

pages = "508--510",

journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",

issn = "0035-9203",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

AU - Ponce, Mario

AU - Ugarte-Gil, Cesar

AU - Zamudio, Carlos

AU - Krapp, Fiorella

AU - Gotuzzo, Eduardo

AU - Seas, Carlos

PY - 2012/8

Y1 - 2012/8

N2 - The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.

AB - The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.

KW - Drug therapy

KW - Failure

KW - Multi-drug resistance

KW - Streptomycin

KW - Treatment outcome

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84863579155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863579155&partnerID=8YFLogxK

U2 - 10.1016/j.trstmh.2012.05.008

DO - 10.1016/j.trstmh.2012.05.008

M3 - Article

C2 - 22742941

AN - SCOPUS:84863579155

SN - 0035-9203

VL - 106

SP - 508

EP - 510

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

IS - 8

ER -

Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this